Biology:IMPDH2
![]() Generic protein structure example |
Inosine-5'-monophosphate dehydrogenase 2, also known as IMP dehydrogenase 2, is an enzyme that in humans is encoded by the IMPDH2 gene.[1][2][3]
Function
IMP dehydrogenase 2 is the rate-limiting enzyme in the de novo guanine nucleotide biosynthesis. It is thus involved in maintaining cellular guanine deoxy- and ribonucleotide pools needed for DNA and RNA synthesis. IMPDH2 catalyzes the NAD-dependent oxidation of inosine-5'-monophosphate into xanthine-5'-monophosphate, which is then converted into guanosine-5'-monophosphate.[1] IMPDH2 has been identified as an intracellular target of the natural product sanglifehrin A[4]
Clinical significance
This gene is up-regulated in some neoplasms, suggesting it may play a role in malignant transformation.[1]
See also
References
- ↑ 1.0 1.1 1.2 "Entrez Gene: IMP (inosine monophosphate) dehydrogenase 2". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3615.
- ↑ "Two distinct cDNAs for human IMP dehydrogenase". J. Biol. Chem. 265 (9): 5292–5. March 1990. doi:10.1016/S0021-9258(19)34120-1. PMID 1969416.
- ↑ "Assignment1 of inosine '-monophosphate dehydrogenase type 2 (IMPDH2) to human chromosome band 3p21.2 by in situ hybridization". Cytogenet. Cell Genet. 82 (3–4): 145–6. 1998. doi:10.1159/000015088. PMID 9858805. https://zenodo.org/record/1235297.
- ↑ "IMPDH2 Is an Intracellular Target of the Cyclophilin A and Sanglifehrin A Complex". Cell Rep. 18 (2): 432–442. 10 January 2017. doi:10.1016/j.celrep.2016.12.030. PMID 28076787.
Further reading
- "IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element". Genet Test Mol Biomarkers 13 (6): 841–7. 2009. doi:10.1089/gtmb.2009.0096. PMID 19810816.
- "A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity". Pharmacogenet. Genomics 17 (4): 283–90. 2007. doi:10.1097/FPC.0b013e328012b8cf. PMID 17496727.
- "Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population". Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (1): 103–13. 2010. doi:10.1002/ajmg.b.30961. PMID 19367581. http://ir.psych.ac.cn/handle/311026/10097.
- "Association of four DNA polymorphisms with acute rejection after kidney transplantation". Transpl. Int. 21 (9): 879–91. 2008. doi:10.1111/j.1432-2277.2008.00679.x. PMID 18444945.
- "Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients". The Journal of Heart and Lung Transplantation 29 (5): 509–516. 2010. doi:10.1016/j.healun.2009.11.602. PMID 20061166.
- "Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism". Pharmacogenet. Genomics 19 (8): 626–34. 2009. doi:10.1097/FPC.0b013e32832f5f1b. PMID 19617864.
- "Prognostic significance of drug-regulated genes in high-grade osteosarcoma". Mod. Pathol. 20 (10): 1085–94. 2007. doi:10.1038/modpathol.3800937. PMID 17660802.
- "A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration". Cell 125 (4): 801–14. 2006. doi:10.1016/j.cell.2006.03.032. PMID 16713569.
- "Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis". Int J Colorectal Dis 24 (11): 1271–9. 2009. doi:10.1007/s00384-009-0759-2. PMID 19597826.
- "Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells". FEBS J. 272 (3): 696–710. 2005. doi:10.1111/j.1742-4658.2004.04504.x. PMID 15670151.
- "An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid". Pharmacogenomics J. 10 (1): 70–6. 2010. doi:10.1038/tpj.2009.43. PMID 19770842.
- "Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients". Ther Drug Monit 29 (6): 735–42. 2007. doi:10.1097/FTD.0b013e31815d8ace. PMID 18043470.
- "Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation". Clin. Pharmacol. Ther. 83 (2): 328–35. 2008. doi:10.1038/sj.clpt.6100300. PMID 17713475.
- "Interpopulation variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms". Genet. Test. 12 (4): 513–6. 2008. doi:10.1089/gte.2008.0049. PMID 18976158.
- "Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells". Cell Cycle 7 (15): 2392–400. 2008. doi:10.4161/cc.6390. PMID 18677108.
- "Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase". Bioorg. Med. Chem. 16 (15): 7462–9. 2008. doi:10.1016/j.bmc.2008.06.003. PMID 18583139.
- "Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress". Biochem. Biophys. Res. Commun. 337 (4): 1308–18. 2005. doi:10.1016/j.bbrc.2005.09.191. PMID 16236267.
- "Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes in Japanese individuals". Drug Metab. Pharmacokinet. 24 (6): 557–64. 2009. doi:10.2133/dmpk.24.557. PMID 20045992.
- "Large-scale mapping of human protein-protein interactions by mass spectrometry". Mol. Syst. Biol. 3 (1): 89. 2007. doi:10.1038/msb4100134. PMID 17353931.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
![]() | Original source: https://en.wikipedia.org/wiki/IMPDH2.
Read more |